COMP <GO>
MRK vs ABBV // FREE CASH FLOW YIELD
Merck & Company Inc. Common Stock (new) (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MRK 6
— ABBV 8
▲ FREE CASH FLOW YIELD LEADER: ABBV
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
fcf-yield
3.42%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRK VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRK | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.80% | 70.20% | +4.60 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.70% | 29.00% | -8.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.3x | 33.3x | -18.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 3.42% | 3.47% | -0.05 | ABBV | /fcf-yield <GO> |
| Operating Margin | 34.30% | 24.60% | +9.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | 28.10% | 6.90% | +21.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 1.30% | 8.60% | -7.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.26% | 2.27% | -0.01 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.19 | 5.33 | -0.14 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.40% | -0.80 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 72.8 | -15.92 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.92 | 1.15 | -0.23 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.4x | 113.1x | -94.70 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $361.02B | $513.86B | -$152.84B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRK REV | ABBV REV | MRK GROSS % | ABBV GROSS % | MRK FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $65.01B | $61.16B | 74.8% | 70.2% | $12.36B | $17.82B |
| FY 2024 | $64.17B | $56.33B | 76.3% | 70.0% | $18.10B | $17.83B |
| FY 2023 | $60.12B | $54.32B | 44.0% | 44.0% | $10.30B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRK // BETA 0.92
ABBV // BETA 1.15